Bionano expects full year 2023 revenue to be in the range of $35M to $38M, which would represent a range 26% to 37% growth over full year 2022 revenue. We anticipate the installed base of OGM systems will total 325 by the end of 2023.Chris Stewart, chief financial officer at Bionano added, "Q4 2022 was an outstanding quarter, capping off a tremendous year where we achieved impressive year-over-year revenue growth of 30%. We leveraged our strong balance sheet to acquire Purigen Biosystems and their industry leading isotachophoresis (ITP) solution for DNA isolation and analysis on the Ionic( Purification System in Q4 2022. We begin 2023 well-positioned, and look forward to executing on our goal to drive value for our stakeholders."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BNGO:
- Bionano Genomics options imply 14.3% move in share price post-earnings
- Bionano Genomics announces publication of results from OGM trial
- Bionano Genomics options imply 13.9% move in share price post-earnings
- Bionano Genomics obtains class I registrations from China’s NMPA
- Bionano Announces China NMPA Approval for DNA Extraction and Labeling Products for IVD Use in Hematologic Malignancies
